Abstract 5225
Background
Chemotherapy-induced alopecia (CIA) is a common and distressing side effect of chemotherapy treatment. Significant progress has been made during the past 2 decades in treating many of the side effects associated with cancer chemotherapy including emesis, hematopoietic cytopenias, xerostomia, infection, pain, and thrombosis. Similar progress has not been made in the prevention of CIA, apart from scalp cooling. We set out to examine the uptake, patient satisfaction and efficacy (as perceived by medical staff and patients) of scalp cooling treatment among patients receiving chemotherapy.
Methods
We reviewed a prospectively maintained database of patients who were offered scalp cooling treatment in our oncology dayward between 01/10/2014 and 22/06/2018. We analysed patient uptake and efficacy as perceived and recorded by medical staff (“medical efficacy”). A questionnaire was sent to patients who had accepted scalp cooling treatment and were alive at follow-up, to assess patient perceived efficacy and patient satisfaction. Patient perceived efficacy was compared to medical efficacy using the Fisher’s exact test.
Results
The mean age was 60.1 (SD 10.9) and 91.4% of the patients were female. Uptake for scalp cooling was 49% (120/245). 75% (90/120) of patients were alive at follow up and 51% (46/90) responded to the questionnaire. Scalp cooling was considered efficacious in 63% (29/46) of patients, versus 43.3% (52/120) as assessed by the medical team, Fishers test p = 0.0253. 86.9% of patients who accepted scalp cooling and responded to the questionnaire (40/46) agreed or strongly agreed that they were satisfied with their choice to try scalp cooling, and 67.4% (31/46) agreed or strongly agreed that their experience of scalp cooling was a positive one. There was a strong association between patient perceived efficacy and satisfaction (p < 0.001).
Conclusions
The use of scalp cooling to prevent chemotherapy induced alopecia is an effective treatment in our real-world population. Patients were more likely than the medical team to consider scalp cooling treatment effective. We found high levels of patient satisfaction with the decision to try scalp cooling, even among patients whose treatment was ineffective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
Presenter: Baohui Han
Session: Poster Display session 1
Resources:
Abstract
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract